33 results about "Macrophage polarization" patented technology

The invention discloses a simple porification and one-step deposition method of polyether-ether-ketone. The method uses a polydopamine and gentamicin coating to modify the surface of three-dimensional porous polyether-ether-ketone to realize the anti-bacteria effect and regulate macrophage polarization and inflammatory reaction, thereby preventing bacterial colonization and promoting osseointegration. In-vitro research results show that the polydopamine / gentamicin modified porous polyether-ether-ketone can more easily induce macrophages to differentiate into M2 types, has a relatively strong continuous killing effect on staphylococcus aureus and escherichia coli, has relatively high antibacterial and anti-inflammatory capabilities, and can be used as a novel implant material for clinical orthopedics. In-vivo experiment results show that the three-dimensional porous polyether-ether-ketone surface modified polydopamine / gentamicin can well control bacterial infection and promote osseointegration. The invention shows that the polyether-ether-ketone is porous, so that polydopamine and gentamicin can be immobilized at the same time, and the surface-activated polyether-ether-ketone has antibacterial, anti-inflammatory and osseointegration capabilities, and has relatively high application potential in regenerative medicine.

The invention provides an application of a TIGIT-ECD recombinant protein in resisting allogeneic immunological rejection. The amino acid sequence of the recombinant protein TIGIT-ECD is shown as SEQ ID NO:1. The nucleotide sequence coding the recombinant protein TIGIT-ECD is shown as SEQ ID NO:2. The recombinant protein is capable of effectively regulating macrophage polarization by activating a TIGIT-CD155 signal path, and contributes to inducing allogeneic graft tolerance. Therefore, the recombinant protein TIGIT-ECD can serve as a graft rejective reaction inhibitor, and can also be appliedto preparing drugs for preventing and treating the graft rejective reaction.

The present disclosure concerns the use of an anti-SIRPa compound able to inhibit the polarization of anti-inflammatory M2-type macrophages and / or favors pro-inflammatory M1-type macrophages. In a preferred embodiment, such compound is used to treat cancer. Interestingly, this disclosure allows to treat cancer through an indirect pathway involving the immune system.

The present invention examines the interaction between an angiopoietin-1 mimetic peptide, QHREDGS (glutamine-histidine-arginine-glutamic acid-aspartic acid-glycine-serine (SEQ ID NO: 1)) immobilized to a collagen-chitosan hydrogel, and murine bone marrow derived macrophages. When macrophages were cultured in the presence of the peptide conjugated to a hydrogel, both pro-inflammatory and anti-inflammatory cytokines were produced, in contrast to the application of soluble peptide which elicited minimal cytokine secretion. This indicates a unique macrophage polarization with covalently immobilized peptide hydrogels, which can be beneficial in the context of the wound microenvironment.

The invention provides a recombinant fusion protein TIGIT-Fc and application in resisting transplant rejection thereof. The linear tandem polypeptide is capable of inducing specific T cell response toexert an immunoprotective effect. The amino acid sequence of the recombinant fusion protein TIGIT-Fc is shown in SEQ ID NO: 1. The nucleotide sequence for encoding the recombinant fusion protein TIGIT-Fc is shown in SEQ. ID. NO: 2. The recombinant fusion protein TIGIT-Fc can effectively regulate macrophage polarization by interfering CD226 / TIGIT-CD155 signaling pathways, which is conducive to theinduction of allograft tolerance.

The invention relates to the technical field of biomedical engineering materials, and discloses a hydrogel wound dressing with antibacterial and immunoregulation functions, and a preparation method thereof. The hydrogel wound dressing comprises hydrogel, black phosphorus nanosheets loaded in the hydrogel and folic acid modified polyethyleneimine nanoparticles, and the folic acid modified polyethyleneimine nano particles are loaded with MicroRNA-223*. MicroRNA-223* which has a regulation and control function on macrophage polarization is loaded on polyethyleneimine, folic acid modified polyethyleneimine has a better targeting effect on macrophages, black phosphorus nanosheets and polyethyleneimine form nanoparticles due to electrostatic interaction, and the nanoparticles respectively have photodynamic and photothermal effects under the irradiation of near-infrared laser with the wavelength of 660 nm and the wavelength of 808 nm, so that biological membranes and structures of bacteria at the wound surface are destroyed, and the antibacterial effect is achieved; and meanwhile, the nanoparticles release the MicroRNA-223 *, the immune regulation function is played, the wound healing is promoted, and the scar formation is reduced.

The invention discloses an application of a proteasome inhibitor in anti-cancer drugs. The proteasome inhibitor comprises Carfilzomib (carfilzomib), Bortezomib (bortezomib), MLN9708 (ixazomib), MG132and the like. The targeted cancer is a cancer in which macrophage polarization participates, i.e., a tumor in which the macrophage type is mainly M2 type in a tumor microenvironment, including a solidtumor and a hematologic tumor, and also including an in-situ cancer and a transplanted cancer. It is found through a large amount of creative work that the proteasome inhibitor converts M2 type TAM in the tumor immune microenvironment into M1 type TAM, thereby improving the tumor microenvironment, promoting the phagocytic effect of macrophages on tumor cells and increasing infiltration of immunecells on tumors to inhibit tumor growth.

The invention discloses use of corilagin in preparation of anti-myocardial fibrosis medicines, belonging to the technical field of biological medicine. By constructing an in-vivo myocardial fibrosis model induced by a mouse aortic ligation operation and an in-vitro myocardial fibrosis model of transforming growth factor (TGF)-beta-induced rat suckling CFs for performing experimental study, the results show that the corilagin can regulate macrophage polarization so as to inhibit inflammation, also can down-regulate an interleukin-4 (IL-4) receptor so as to avoid excessive production of TGF-beta, and inhibits the expression of a TGF-beta receptor so as to reduce the activation of cardiac fibroblasts, thereby reducing collagen content and relieving myocardial fibrosis. The corilagin providedby the invention can reduce the myocardial fibrosis caused by long-term stress load, protect heart tissues and inhibit or delay deterioration of heart functions; the corilagin has a significant effectin the aspect of anti-myocardial fibrosis, is little in side effects, and can be used for preparing the anti-myocardial fibrosis medicines.

The invention discloses a preparation method of a zin-ion-containing tissue engineering scaffold with an anti-inflammatory function. The method comprises the following steps: separating Wharton's jelly from a human umbilical cord; preparing a pure Wharton's jelly scaffold through the processes of repeated low-temperature crushing, freeze thawing, gradient centrifugation, pancreatin digestion and elution, vacuum freeze compression drying and the like; performing induced deposition on the pure Wharton jelly scaffold in simulated body fluid containing zinc ions; putting the scaffold in an ammoniawater solution in a hydrothermal kettle and performing a gas-phase hydrothermal reaction; and then performing vacuum freeze drying to obtain the cartilage tissue engineering scaffold containing zincions. The tissue engineering scaffold prepared by the method not only has high histocompatibility but also can successfully load zinc ions and release the zinc ions through a slow release effect, so that macrophage polarization is regulated and an anti-inflammatory effect on cartilage injury in an inflammatory environment is realized; and stem cells can be induced to differentiate into chondrocytes; and a good internal immune environment is provided for cartilage repair.

The invention relates to the field of biotechnology, in particular to a macrophage polarization inhibitor and application thereof. A macrophage polarization inhibitor Dnmt3aos, a kit containing the inhibitor Dnmt3aos claimed in Claim 1 and the application of the macrophage polarization inhibitor Dnmt3aos are provided. The Dnmt3aos plays a crucial role in macrophage polarization, Dnmt3aos-Dnmt3a axis-mediated DNA aberrant methylation may play a key role in the macrophage polarization, and the inhibitor enriches the understanding of the macrophage polarization mechanism and provides theoreticaldata support for studying the macrophage polarization.

The invention relates to a pharmaceutical composition containing a gefitinib and histone deacetylase inhibitor, a lipidosome preparation of the pharmaceutical composition, and application of the pharmaceutical composition and the lipidosome preparation to preparing medicines for treating the EGFRT790M mutation drug-fast non-small cell lung cancer. The histone deacetylase inhibitor is preferentially Vorinostat and TMP195. Particularly, the invention further relates to a double-target co-carrier liposome, wherein the surface of the liposome is modified by herceptin and mannose, and the liposomecontains the pharmaceutical composition. The double-target co-carrier liposome can be used for controlling the macrophage polarization and can be used for treating the non-small cell lung cancer withEGFRT790M mutation.

Disclosed are a use of FATS gene, by knocking out or inhibiting the FATS gene, in promoting macrophage polarization into M1 type and / or inhibiting macrophage polarization into M2 type, or activating and proliferating killer T cells; and a use of FATS gene or an expression product thereof in any one of i) developing and screening a functional product for tumors and ii) preparing a functional product for treatment or prevention of tumors. The present application demonstrates that FATS gene or an expression product thereof is closely related to tumors, and thus can be used as a drug target to develop tumor-related drugs. Cellular and molecular mechanisms of the FATS gene or its expression product in tumors are further demonstrated, providing an effective targeting means or a major basis for the development of tumor-related drugs.

The invention provides a method for regulating the polarization state of macrophages. The method comprises the step of activating cholinergic anti-inflammatory pathways of the macrophages by adoptingcholinergic anti-inflammatory pathway agonists and / or vagus nerve electrical stimulation signals. According to the method in the invention, the cholinergic anti-inflammatory pathway agonists are adopted to stimulate the macrophages in vitro; or the electrical stimulation signals are adopted to stimulate vagus nerves in vivo; therefore, the cholinergic anti-inflammatory pathways are activated; polarization of M1 type macrophages is inhibited; polarization of M2 type macrophages is promoted; a regulating effect on macrophage polarization types is achieved; and the method has the important significance in the aspects of specifically regulating the functions of the polarized macrophages and diseases caused by the polarized macrophages.

The invention relates to the technical field of chemical medicines, in particular to a supermolecule precursor, a supermolecule assembly and a method for regulating and controlling macrophage polarization. The supermolecule precursor comprises polycation modified by cyclodextrin, and adamantine-polyethylene glycol-active polypeptide loaded to the polycation modified by cyclodextrin, wherein an active peptide raw material for forming the adamantine-polyethylene glycol-active polypeptide can be the polypeptide capable of regulating and controlling the macrophage polarization. The supermolecule precursor can effectively regulate and control polarization from macrophage to M2 macrophage, meanwhile, the supermolecule precursor can load RNA, and therefore, the supermolecule assembly can furtherregulate and control the macrophage polarization so as to accelerate the macrophage to be converted into the M2 macrophage.

The invention provides an in vitro method for inducing macrophage polarization to an M2 phenotype useful for tissue repair. The method described in the present invention comprises the in vitro exposure of macrophages to repeated series of hypoxia-reoxygenation. Activated M2 macrophages obtained by this method overexpress molecules important for tissue remodeling and amelioration of inflammation, such as NGAL and anti-inflammatory cytokines (IL-10). Thus, M2 macrophages obtained by this method are useful as cell therapy for tissue regeneration. The invention also provides pharmaceutical compositions and kits comprising the M2 macrophages obtained by the described method. The invention further refers to a device for inducing hypoxia and re-oxygenation conditions on isolated macrophages according to the described method.

Ophthalmic devices coated with an active agent eluting coating are provided herein. Placement of the coated ophthalmic devices on the surface of eye results in modulation of cells responding to an immune modifying agent and reducing inflammation-related complications in the eye. Methods for treating ocular disorders are also provided herein. The disclosed subject matter is based, in part, on the discovery that ophthalmic devices coated with a cytokine eluting coating can shift early-stage macrophage polarization associated with alleviation of symptoms and causes of inflammatory ocular disorders.

The invention discloses a macrophage-based living cell drug-carrying system, a preparation method and application thereof. The macrophage-based live cell drug delivery system comprises macrophages, anchored chemotherapeutic drugs and anchored cytolytic groups. The preparation method includes the following steps: taking mouse bone marrow cells, culturing them in vitro, adding recombinant mouse macrophage colony stimulating factor and mouse breast cancer 4T1 cell culture supernatant or lipopolysaccharide LPS into the culture medium, and continuing to culture, Induce macrophage polarization to obtain regulatory M1 or M2 macrophages; co-incubate anchored chemotherapeutic drugs and anchored cytolytic groups in macrophage culture medium to prepare macrophage-based Live cell drug delivery system. The macrophage-based living cell drug-loading system prepared above can actively target the lung metastasis site of breast cancer, and effectively inhibit the lung metastasis of breast cancer.

The present disclosure concerns the use of an anti-SIRPa compound able to inhibit the polarization of anti-inflammatory M2-type macrophages and / or favors pro-inflammatory M1-type macrophages. In a preferred embodiment, such compound is used to treat cancer. Interestingly, this disclosure allows to treat cancer through an indirect pathway involving the immune system.

The invention provides a mesenchymal stem cell preparation for treating diabetic cutaneous ulcers and a preparation method of the mesenchymal stem cell preparation. The mesenchymal stem cell preparation comprises hydrocolloid gel and mesenchymal stem cells, wherein the hydrocolloid gel comprises sodium carboxymethyl cellulose and pectin, and the molar ratio of the sodium carboxymethyl cellulose to the pectin is (80-100): 1. According to the mesenchymal stem cell preparation, the specific hydrocolloid gel is adopted to carry the mesenchymal stem cells, so that the residence time of the mesenchymal stem cells in a wound part is effectively prolonged, implantation of the mesenchymal stem cells is promoted, the wound healing rate of the diabetic cutaneous ulcers is remarkably increased, the mesenchymal stem cell preparation effectively promotes skin tissue regeneration, promotes new angiogenesis and regulates macrophage polarization, which indicates that the mesenchymal stem cell preparation disclosed by the invention is suitable for preventing and / or treating the diabetic cutaneous ulcers.

The invention mainly relates to a macrophage polarization regulator and application thereof in promoting platelet generation. Specifically, the present invention relates to a pharmaceutical composition for treating thrombocytopenic disease in a subject, and the composition comprises the macrophage polarization regulator and a pharmaceutically acceptable carrier. The invention also relates to a kitfor diagnosing thrombocytopenic disease in the subject, and the kit comprises a detection reagent for detecting a thrombocytopenic disease marker and / or a detection reagent for detecting macrophage polarization level. The invention also relates to the macrophage polarization regulator, the detection reagent for detecting the marker and application of the detection reagent for detecting the macrophage polarization level in the thrombocytopenic disease. The invention has important clinical significance for hierarchical diagnosis of diseases and accurate targeted therapy of diseases.

The invention discloses application of an IL-6R inhibitor and IL-4R inhibitor combined drug in breast cancer chemotherapy drugs. IL-4 participates in promoting macrophage M2 polarization, IL-6 is a multi-effect cell factor with wide functions, and IL-4 and IL-6 participate in regulating growth and differentiation of various cells, have the functions of regulating immune response, acute phase reaction and hematopoiesis and play an important role in anti-infection immune response of the body. In the tumor microenvironment, IL-4 and IL-6 participate in promoting macrophage polarization, IL-4 andIL-6 synergistically act in the later stage of tumor development to promote macrophage M2 polarization, and IL-4 and IL-6 have an anti-inflammatory effect and can promote tumor development. The effectof the IL-6R inhibitor and IL-4R inhibitor combined drug in the breast cancer chemotherapy drugs is researched through the synergistic effect of the IL-6R inhibitor and IL-4R inhibitor.

The present invention discloses a composition with a macrophage polarization targeted adjustment function and a preparation method and application thereof. The composition comprises a targeting carrier capable of targeting macrophages and nano iron oxide coating the interior of the targeting carrier. The targeting carrier coats the nano iron oxide to change the surface structure and performance ofthe nano iron oxide, so that the nano iron oxide can better avoid identification of the macrophages, phagocytosis of nanoparticles by the macrophages is reduced, and the active targeting property ofthe nano iron oxide to a tumor tissue is improved; and the nano iron oxide particles have the potential of polarizing the macrophages, and can change tumor microenvironment components, thereby inhibiting tumor recurrence and metastasis.

The invention provides a recombinant fusion protein TIGIT‑Fc and its application in anti-graft rejection. The linear tandem polypeptide can induce specific T cell response to exert immune protection. The amino acid sequence of the recombinant fusion protein TIGIT-Fc is shown in SEQ ID NO:1. The nucleotide sequence encoding the recombinant fusion protein TIGIT-Fc is shown in SEQ.ID.NO:2. The recombinant fusion protein TIGIT‑Fc disclosed in the present invention can effectively regulate the polarization of macrophages by intervening in the CD226 / TIGIT‑CD155 signaling pathway, and is helpful for inducing allograft tolerance.

The invention discloses construction of a photosensitive nano-micelle capable of inducing M1 type polarization of tumor-associated macrophages and an anti-tumor application of the photosensitive nano-micelle. According to the preparation method, the photosensitizer is connected to the block copolymer containing the polyarginine, then the block copolymer is self-assembled into the nano-micelle PLAC to serve as a carrier, and the PLAC has a good M1 macrophage polarization effect; meanwhile, the nano-micelle PLAC is further loaded with an immune agonist to obtain nano-particles, and after the nano-micelle PLAC is loaded with the immune agonist, the polarization effect is stronger. The constructed nano system has the characteristics of releasing an immune agonist in response to a tumor microenvironment and generating ROS and NO in light response, immune cells can be further activated through transmembrane expression of HSP70, more NO is generated to form a positive feedback cycle, photodynamic therapy and immunotherapy are achieved at the same time, and the nano system has a good application prospect. A new thought is provided for improving the prognosis of the patient with the highly metastatic tumor.

The invention discloses a method for researching the influence on macrophage polarization by PPARs. The method comprises the following steps: detecting the expression level of macrophage RRARs and regulation on macrophage polarization by establishing an echinococcus granulosus infected mouse model and an in-vitro protoscolex and macrophage co-culture system, inhibiting a PPARs passage on the basis, and further discussing the influence on macrophage polarization by the PPARs as well as the effect in the echinococcosis immune escape process.

The invention discloses application of monomer luteolin coming from vegetables and fruits and Chinese herbal medicine, and particularly relates to the influence and mechanism of the luteolin coming from vegetables and fruits and Chinese herbal medicine on the macrophage polarization mode and new application of the luteolin in the anti-inflammation aspect. Different polarization modes of macrophages have important significance in development and prognosis of tumors, angiocardiopathy, nephrosis, inflammations and the like. Induction of M1-type polarization of the macrophages is stimulated with bacterial endotoxin lipopolysaccharide and interferon-gamma; induction of M2-type polarization is stimulated with IL-4; after the luteolin is adopted for treatment, the morphological change of the macrophages and expression of marking molecules of the macrophages after M1-type polarization and M2-type polarization are observed; an immunoblotting technology is adopted for detecting the expression ofa protein channel. It is found that the luteolin can down-regulate M1-type pro-inflammatory cytokines and up-regulate M2-type pro-inflammatory cytokines; meanwhile, protein p-STAT3 is horizontally down-regulated, and p-STAT6 is up-regulated, that is to say, the luteolin regulates the polarization of the M1 / M2 macrophages through the protein channel STATs, and thus the anti-inflammatory effect isachieved.

The invention provides an in vitro method for inducing macrophage polarization to an M2 phenotype. The method comprises the in vitro exposure of macrophages to repeated series of hypoxia-reoxygenation. Activated M2 macrophages obtained by this method overexpress molecules important for tissue remodeling and amelioration of inflammation, thus they are useful as cell therapy for tissue regeneration. The invention also provides pharmaceutical compositions and kits comprising the M2 macrophages obtained by the method, as well as a device for inducing hypoxia and re-oxygenation conditions on isolated macrophages according to the method.

The invention discloses application of IL-33 in preparing mesenchymal stem cell immunoregulatory preparations. A recombinant allosome MSCs for regulating an immune reaction is built, IL-33 is used formodifying MSCs, the survival rate of the MSCs in a low-oxygen condition is improved, and the immunosuppressive function of the MSCs is improved by improving the influence of the allosome MSCs on macrophage polarization. The invention further discloses application of recombinant mesenchymal stem cells in preparing drugs for treating myocardial infarction. The drugs can treat the myocardial infarction through allosome cell transplantation.